Title: 2,2',4,4'-Tetrachlorobiphenyl upregulates cyclooxygenase-2 in HL-60 cells via p38 mitogen-activated protein kinase and NF-kappaB.

Authors: Bezdecny, Steven A; Karmaus, Peer; Roth, Robert A; Ganey, Patricia E

Published In Toxicol Appl Pharmacol, (2007 Jun 15)

Abstract: Polychlorinated biphenyls (PCBs) are ubiquitous, persistent environmental contaminants that affect a number of cellular systems, including neutrophils. Among the effects caused by the noncoplanar PCB 2,2',4,4'-tetrachlorobiphenyl (2244-TCB) in granulocytic HL-60 cells are increases in superoxide anion production, activation of phospholipase A(2) with subsequent release of arachidonic acid (AA) and upregulation of the inflammatory gene cyclooxygenase-2 (COX-2). The objective of this study was to determine the signal transduction pathways involved in the upregulation of COX-2 by 2244-TCB. Treatment of HL-60 cells with 2244-TCB led to increased expression of COX-2 mRNA. This increase was prevented by the transcriptional inhibitor actinomycin D in cells pretreated with 2244-TCB for 10 min. The increase in COX-2 mRNA was associated with release of (3)H-AA, phosphorylation of p38 and extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinases, increased levels of nuclear NF-kappaB and increased superoxide anion production. Bromoenol lactone, an inhibitor of the calcium-independent phospholipase A(2), reduced (3)H-AA release but had no effect on COX-2 mRNA, protein or activity. Pretreatment with SB-202190 or SB-203580, inhibitors of the p38 MAP kinase pathway, prevented the 2244-TCB-mediated induction of COX-2 and phosphorylation of p38 and ERK MAP kinases. These inhibitors did not alter (3)H-AA release. Treatment with PD 98059 or U 0126, inhibitors of the MAP/ERK (MEK) pathway, prevented the 2244-TCB-mediated activation of ERK but had no effect on COX-2 induction or p38 phosphorylation. 2244-TCB treatment did not affect c-Jun N-terminal kinase (JNK) phosphorylation. 2244-TCB exposure increased the amount of nuclear NF-kappaB. This increase was prevented by pretreatment with p38 MAP kinase inhibitors, but not by pretreatment with MEK inhibitors. Pretreatment with inhibitors of NF-kappaB prevented the 2244-TCB-mediated induction of COX-2 mRNA. 2244-TCB-mediated increases in superoxide anion were prevented by the NADPH oxidase inhibitor apocynin or the free radical scavenger 4-hydroxy TEMPO, but neither of these inhibitors affected the 2244-TCB-induced changes in COX-2 mRNA levels or (3)H-AA release. Taken together these data suggest that p38 MAP kinase-dependent activation of NF-kappaB is critical for the 2244-TCB-mediated upregulation of COX-2 mRNA.

PubMed ID: 17482227

MeSH Terms: Analysis of Variance; Arachidonic Acid/metabolism; Cell Line; Cyclooxygenase 2/drug effects*; Cyclooxygenase 2/genetics; Cyclooxygenase 2/metabolism; Environmental Pollutants/pharmacology*; Enzyme Inhibitors/pharmacology; Granulocyte Precursor Cells/drug effects; Granulocyte Precursor Cells/enzymology; Humans; NF-kappa B/drug effects*; NF-kappa B/metabolism; Polychlorinated Biphenyls/pharmacology*; RNA, Messenger/analysis; Signal Transduction/drug effects*; Statistics, Nonparametric; Superoxides/metabolism; Transcriptional Activation/drug effects; Up-Regulation/drug effects; p38 Mitogen-Activated Protein Kinases/drug effects*; p38 Mitogen-Activated Protein Kinases/metabolism